192 related articles for article (PubMed ID: 32800674)
21. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants.
Doh RM; Park HJ; Rhee Y; Kim HS; Huh J; Park W
Implant Dent; 2015 Apr; 24(2):222-6. PubMed ID: 25734949
[TBL] [Abstract][Full Text] [Related]
22. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws.
Kwon YD; Lee DW; Choi BJ; Lee JW; Kim DY
Osteoporos Int; 2012 Nov; 23(11):2721-5. PubMed ID: 22218418
[TBL] [Abstract][Full Text] [Related]
23. Management of bisphosphonate-related osteonecrosis of the jaw: a literature review.
Spanou A; Lyritis GP; Chronopoulos E; Tournis S
Oral Dis; 2015 Nov; 21(8):927-36. PubMed ID: 25732104
[TBL] [Abstract][Full Text] [Related]
24. Histopathological Effects of Teriparatide in Medication-Related Osteonecrosis of the Jaw: An Animal Study.
Keskinruzgar A; Bozdag Z; Aras MH; Demir T; Yolcu U; Cetiner S
J Oral Maxillofac Surg; 2016 Jan; 74(1):68-78. PubMed ID: 26215490
[TBL] [Abstract][Full Text] [Related]
25. Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Ohbayashi Y; Miyake M; Sawai F; Minami Y; Iwasaki A; Matsui Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Apr; 115(4):e31-7. PubMed ID: 23246226
[TBL] [Abstract][Full Text] [Related]
26. Risk-reductive dental strategies for medication related osteonecrosis of the jaw among cancer patients: A systematic review with meta-analyses.
Karna H; Gonzalez J; Radia HS; Sedghizadeh PP; Enciso R
Oral Oncol; 2018 Oct; 85():15-23. PubMed ID: 30220314
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis.
El-Rabbany M; Sgro A; Lam DK; Shah PS; Azarpazhooh A
J Am Dent Assoc; 2017 Aug; 148(8):584-594.e2. PubMed ID: 28527518
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the effect of teriparatide therapy on mandibular fracture healing in rats with medication-related osteonecrosis of the jaw.
Zandi M; Dehghan A; Amini P; Doulati S; Rezaeian L
Clin Oral Investig; 2019 Nov; 23(11):3987-3993. PubMed ID: 30715621
[TBL] [Abstract][Full Text] [Related]
29. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw.
Heifetz-Li JJ; Abdelsamie S; Campbell CB; Roth S; Fielding AF; Mulligan JP
Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Nov; 128(5):491-497.e2. PubMed ID: 31488389
[TBL] [Abstract][Full Text] [Related]
31. Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review.
Cavalcante RC; Tomasetti G
J Craniomaxillofac Surg; 2020 Nov; 48(11):1080-1086. PubMed ID: 32998853
[TBL] [Abstract][Full Text] [Related]
32. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
33. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report.
Javelot MJ; Sergheraert J; Agbo-Godeau S; Levy-Weil F; Laurence S; Goudot P; Khonsari RH; Mauprivez C
J Stomatol Oral Maxillofac Surg; 2020 Jun; 121(3):300-304. PubMed ID: 31301390
[TBL] [Abstract][Full Text] [Related]
34. Short-term perioperative teriparatide therapy for the prevention of medication-related osteonecrosis of the jaw: A randomized, controlled preclinical study in rats.
Zandi M; Dehghan A; Mohammadi-Mofrad A; Amini P; Vahdatinia F
J Craniomaxillofac Surg; 2017 Feb; 45(2):275-280. PubMed ID: 28087282
[TBL] [Abstract][Full Text] [Related]
35. Are We Ready to Use Teriparatide to Treat Medication-Related Osteonecrosis of the Jaw in Clinical Practice?
Ripamonti CI; Napoli N
J Clin Oncol; 2020 Sep; 38(26):2949-2951. PubMed ID: 32658629
[No Abstract] [Full Text] [Related]
36. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
37. Weak evidence for the management of medication-related osteonecrosis of the jaw: An overview of systematic reviews and meta-analyses.
Moraschini V; Calasans-Maia MD; Louro RS; Arantes EBR; Calasans-Maia JA
J Oral Pathol Med; 2021 Jan; 50(1):10-21. PubMed ID: 32589782
[TBL] [Abstract][Full Text] [Related]
38. Teriparatide Treatment for Medication-Related Osteonecrosis of the Jaw: Is This an Effective Option?
Myoken Y; Fujita Y; Toratani S
J Clin Oncol; 2021 Jan; 39(2):172-173. PubMed ID: 33290129
[No Abstract] [Full Text] [Related]
39. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
40. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
